Zimmer Holdings is a global leader in the development and manufacture of orthopaedic implants and related products, focusing on enhancing the quality of life for individuals suffering from conditions related to bones and joints
The company specializes in a wide range of surgical products and services, including joint replacement systems, trauma products, and a variety of surgical instruments. Zimmer Holdings also invests in innovative technologies and solutions to improve surgical outcomes and patient satisfaction, catering to healthcare professionals and institutions worldwide. With a commitment to advancing orthopaedic care, the company plays a crucial role in both the medical community and patient rehabilitation processes.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including BD (NYSEBDX) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at CONMED (NYSECNMD) and the best and worst performers in the surgical equipment & consumables - diversified industry.
BALA CYNWYD, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Medical device company Zimmer Biomet (NYSEZBH) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.3% year on year to $2.02 billion. Its non-GAAP profit of $2.31 per share was 0.8% above analysts’ consensus estimates.
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to close in first half of 2025.
The robotic-assisted surgery trend is accelerating and Intuitive Surgical continues to lead the pack as its continued to keeps its wide moat since 2000.
Medtronic (MDT) and Zimmer Biomet (ZBH) are emerging as serious contenders in robotic surgery, challenging Intuitive Surgical’s (ISRG) market dominance.
We are looking for value in the Healthcare Sector because we are still in a strong bull market that has been not only one of the longest on record, but also has seen the S&P 500 get to one of its lofty valuations ever.
Boston Scientific Co (NYSEBSX) is a global medical device manufacturer that’s seeing a strong influx of investors as shares grind to new all-time highs.
